Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSCT for Fanconi Anemia with Busulfan, Cyclophosphamide, and Fludarabine
NCT03600909Phase 2Terminated
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2018
- Primary completion
- Apr 2021
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of busulfan, cyclophosphamide, fludarabine in Fanconi anemia (FA), myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), sponsored by Memorial Sloan Kettering Cancer Center. Started May 2018; status: terminated.
02
Drugs
busulfancyclophosphamidefludarabine
03
Conditions
Fanconi anemia (FA)myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03600909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03600909.